SWX: ROP

Explore the latest insights on SWX: ROP and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of SWX: ROP’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance
CompanyDeals

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance

Qingfeng Pharmaceutical Group and the China Association Against Epilepsy (CAAE) officially signed a strategic collaboration agreement, committing to a five‑year partnership spanning discipline development, talent cultivation and public welfare assistance.…

Biohaven Licenses MoDE Pan‑IgG Degrader Portfolio to Ono Pharmaceutical in Asia – Up to USD 100 Million in Near‑Term Payments for BHV‑1300 Franchise

Biohaven Licenses MoDE Pan‑IgG Degrader Portfolio to Ono Pharmaceutical in Asia – Up to USD 100 Million in Near‑Term Payments for BHV‑1300 Franchise

Mirxes Partners with Thailand's National Cancer Institute on Blood‑Based Colorectal Cancer Screening – 2,000‑Subject Prospective Triage Study Backs "Cancer Moonshot 2056"

Mirxes Partners with Thailand’s National Cancer Institute on Blood‑Based Colorectal Cancer Screening – 2,000‑Subject Prospective Triage Study Backs “Cancer Moonshot 2056”

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Roche Receives NMPA Approval for Ophthalmology BsAb Vabysmo (Farcimab) for Diabetic Macular Edema

CompanyDrug

Bio-Thera Secures FDA Approval for Avzivi, a Biosimilar to Roche’s Avastin

CompanyDeals

Roche Expands Beyond Oncology with USD 2.7 Billion Carmot Therapeutics Acquisition

CompanyDrug

Roche’s Mosunetuzumab and AnHeart’s Taletrectinib Poised for Priority Review in China

Company

FDA Raises Concerns Over Research Conditions at Roche’s Genentech Trial Site

CompanyDeals

Genentech and NVIDIA Collaborate to Advance Drug Discovery with AI

CompanyDrug

EMA’s CHMP Issues Positive Opinion for Roche’s Tecentriq SC Subcutaneous Formulation

CompanyDrug

Roche’s Lymphoma Therapy Columvi Receives NMPA Approval for Adult Patients with Relapsed DLBCL

Show More